125 related articles for article (PubMed ID: 9885435)
21. Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis.
Passamonti F; Mora B; Barraco D; Maffioli M
Curr Hematol Malig Rep; 2018 Jun; 13(3):173-182. PubMed ID: 29713873
[TBL] [Abstract][Full Text] [Related]
22. Managing patients with myelofibrosis and low platelet counts.
Al-Ali HK; Vannucchi AM
Ann Hematol; 2017 Apr; 96(4):537-548. PubMed ID: 27209535
[TBL] [Abstract][Full Text] [Related]
23. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis.
Mesa RA; Schwager S; Radia D; Cheville A; Hussein K; Niblack J; Pardanani AD; Steensma DP; Litzow MR; Rivera CE; Camoriano J; Verstovsek S; Sloan J; Harrison C; Kantarjian H; Tefferi A
Leuk Res; 2009 Sep; 33(9):1199-203. PubMed ID: 19250674
[TBL] [Abstract][Full Text] [Related]
24. Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis.
Cervantes F; Pereira A; Esteve J; Rafel M; Cobo F; Rozman C; Montserrat E
Br J Haematol; 1997 Jun; 97(3):635-40. PubMed ID: 9207412
[TBL] [Abstract][Full Text] [Related]
25. The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies.
Kreft A; Büche G; Ghalibafian M; Buhr T; Fischer T; Kirkpatrick CJ
Acta Haematol; 2005; 113(2):137-43. PubMed ID: 15802893
[TBL] [Abstract][Full Text] [Related]
26. Primary myelofibrosis and the myeloproliferative neoplasms: the role of individual variation.
Stein BL; Moliterno AR
JAMA; 2010 Jun; 303(24):2513-8. PubMed ID: 20571018
[TBL] [Abstract][Full Text] [Related]
27. Detection of driver and subclonal mutations in myelofibrosis: clinical impact on pharmacologic and transplant based treatment strategies.
Finazzi MC; Lussana F; Salmoiraghi S; Spinelli O; Rambaldi A
Expert Rev Hematol; 2017 Jul; 10(7):627-636. PubMed ID: 28504024
[TBL] [Abstract][Full Text] [Related]
28. Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis.
Le Bousse-Kerdilès MC; Martyré MC
Ann Hematol; 1999 Oct; 78(10):437-44. PubMed ID: 10550553
[TBL] [Abstract][Full Text] [Related]
29. Management of myelofibrosis.
Vannucchi AM
Hematology Am Soc Hematol Educ Program; 2011; 2011():222-30. PubMed ID: 22160038
[TBL] [Abstract][Full Text] [Related]
30. Pathogenesis of myelofibrosis with myeloid metaplasia: Insight from mouse models.
Chagraoui H; Wendling F; Vainchenker W
Best Pract Res Clin Haematol; 2006; 19(3):399-412. PubMed ID: 16781480
[TBL] [Abstract][Full Text] [Related]
31. Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders.
Langabeer SE; Ni Ainle F; Conneally E; Lawler M
Ir J Med Sci; 2007; 176(2):105-9. PubMed ID: 17440677
[TBL] [Abstract][Full Text] [Related]
32. [New insight into pathogenesis of idiopathic myelofibrosis--review].
Xu ZQ; Sun XM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1330-4. PubMed ID: 18088495
[TBL] [Abstract][Full Text] [Related]
33. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2011 Dec; 86(12):1017-26. PubMed ID: 22086865
[TBL] [Abstract][Full Text] [Related]
34. Allogenic hematopoietic stem cell as curative treatment in myelofibrosis.
Wardhana ; Datau EA; Rotty LW; Haroen H
Acta Med Indones; 2011 Oct; 43(4):252-9. PubMed ID: 22156358
[TBL] [Abstract][Full Text] [Related]
35. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients.
Passamonti F; Rumi E; Arcaini L; Boveri E; Elena C; Pietra D; Boggi S; Astori C; Bernasconi P; Varettoni M; Brusamolino E; Pascutto C; Lazzarino M
Haematologica; 2008 Nov; 93(11):1645-51. PubMed ID: 18790799
[TBL] [Abstract][Full Text] [Related]
36. Clinical predictors of outcome in MPN.
Passamonti F; Maffioli M; Merli M; Ferrario A; Caramazza D
Hematol Oncol Clin North Am; 2012 Oct; 26(5):1101-16. PubMed ID: 23009940
[TBL] [Abstract][Full Text] [Related]
37. Ironing out the details of iron overload in myelofibrosis: Lessons from myelodysplastic syndromes.
Carreau N; Tremblay D; Savona M; Kremyanskaya M; Mascarenhas J
Blood Rev; 2016 Sep; 30(5):349-56. PubMed ID: 27106071
[TBL] [Abstract][Full Text] [Related]
38. Stem cell dysregulation in myelofibrosis with myeloid metaplasia: current data on growth factor and transcription factor involvement.
Martyré MC; Le Bousse-Kerdilès MC;
Semin Oncol; 2005 Aug; 32(4):373-9. PubMed ID: 16202683
[TBL] [Abstract][Full Text] [Related]
39. Myelofibrosis: pathogenesis of myelofibrosis with myeloid metaplasia. French INSERM Research Network on Myelofibrosis with Myeloid Metaplasia.
Le Bousse-Kerdilès MC; Martyré MC
Springer Semin Immunopathol; 1999; 21(4):491-508. PubMed ID: 10945038
[No Abstract] [Full Text] [Related]
40. Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis.
Kröger N; Zabelina T; Alchalby H; Stübig T; Wolschke C; Ayuk F; von Hünerbein N; Kvasnicka HM; Thiele J; Kreipe HH; Büsche G
Biol Blood Marrow Transplant; 2014 Jun; 20(6):812-5. PubMed ID: 24589549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
